1-benzyl-5-phenyl-1,2,3,6-tetrahydro-pyridine-4-carboxylic acid | 497843-24-0

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: 1-benzyl-5-phenyl-1,2,3,6-tetrahydro-pyridine-4-carboxylic acid
• 英文别名: 1-Benzyl-5-phenyl-1,2,3,6-tetrahydropyridine-4-carboxylic acid；1-benzyl-5-phenyl-3,6-dihydro-2H-pyridine-4-carboxylic acid
• CAS: 497843-24-0
• 化学式: C₁₉H₁₉NO₂
• 分子量: 293.365
• InChiKey: NJZUJXOKGPNQIK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  40.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-benzyl-5-phenyl-1,2,3,6-tetrahydro-pyridine-4-carboxylic acid 在 palladium on activated charcoal 四磷十氧化物 、 二苯基膦叠氮化物 、 氢气 、 三乙胺 、 三氟乙酸 作用下， 以 甲醇 、 甲苯 为溶剂， 生成 2-(4-Chloro-butyryl)-1,3,4,5-tetrahydro-2H-benzo[c][1,6]naphthyridin-6-one
  参考文献：
  名称：

  Design and synthesis of poly(ADP-ribose)polymerase-1 (PARP-1) inhibitors. Part 3: In vitro evaluation of 1,3,4,5-Tetrahydro-benzo[c][1,6]- and [c][1,7]-naphthyridin-6-ones

  摘要：

  The 1,3,4,5-tetrahydro-benzo[c][1,6]- and [c][1,7]-napthyridin-6-ones are presented as a potent class of PARP-1 inhibitors. Derivatives of these partially saturated aza-5[H]-phenanthridin-6-ones were designed and synthesized with tertiary amines for salt formation. thus enhancing aqueous solubility, iv formulation and their potential use in acute ischemic injuries (i.e., myocardial ischemia and stroke). We found that partial saturation of the C-ring results in derivatives that are several times more potent than the aromatic C-ring derivatives. The general synthetic routes are presented herein as well as thorough in vitro potencies and SAR discussion for selected derivatives. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(03)00465-7
• 作为产物：
  描述：

  1-苄基-3-氧杂-4-哌啶甲酸乙酯 在 lithium hydroxide 、 四(三苯基膦)钯 、 sodium hydride 、 potassium carbonate 作用下， 以 四氢呋喃 、 甲醇 、 乙二醇二甲醚 、 乙醚 为溶剂， 生成 1-benzyl-5-phenyl-1,2,3,6-tetrahydro-pyridine-4-carboxylic acid
  参考文献：
  名称：

  Design and synthesis of poly(ADP-ribose)polymerase-1 (PARP-1) inhibitors. Part 3: In vitro evaluation of 1,3,4,5-Tetrahydro-benzo[c][1,6]- and [c][1,7]-naphthyridin-6-ones

  摘要：

  The 1,3,4,5-tetrahydro-benzo[c][1,6]- and [c][1,7]-napthyridin-6-ones are presented as a potent class of PARP-1 inhibitors. Derivatives of these partially saturated aza-5[H]-phenanthridin-6-ones were designed and synthesized with tertiary amines for salt formation. thus enhancing aqueous solubility, iv formulation and their potential use in acute ischemic injuries (i.e., myocardial ischemia and stroke). We found that partial saturation of the C-ring results in derivatives that are several times more potent than the aromatic C-ring derivatives. The general synthetic routes are presented herein as well as thorough in vitro potencies and SAR discussion for selected derivatives. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(03)00465-7

文献信息

• PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS
  申请人：Knust Henner

  公开号：US20100197697A1

  公开（公告）日：2010-08-05

  The present invention relates to a compounds of formula I wherein A, Ar 1 , Ar 2 , R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , m, n, o, p, s, t, and u are as defined herein or to a pharmaceutically active salt, a racemic mixture, an enantiomer, an optical isomer or a tautomeric form thereof. the present compounds are high potential NK-3 receptor antagonists for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD).

  本发明涉及一种具有以下结构的化合物I，其中A、Ar1、Ar2、R1、R2、R3、R4、R5、R6、m、n、o、p、s、t和u如本文所定义，或者与其药效活性盐、外消旋体混合物、对映体、光学异构体或其互变异构体有关。本化合物是治疗抑郁症、疼痛、精神病、帕金森病、精神分裂症、焦虑和注意缺陷多动障碍（ADHD）的高潜力NK-3受体拮抗剂。
• Sulfonamides and Pharmaceutical Compositions Thereof
  申请人：Estep Kimberly Gail

  公开号：US20100035865A1

  公开（公告）日：2010-02-11

  The invention is directed to a class of compounds, including the pharmaceutically acceptable salts of the compounds, having the structure of formula (I), as defined in the specification. The invention is also directed to compositions containing the compounds of formula (I).

  本发明涉及一类化合物，包括化合物的药学上可接受的盐，具有公式(I)所定义的结构，本发明还涉及含有公式(I)化合物的组合物。
• WO2008/120093
  申请人：——

  公开号：——

  公开（公告）日：——
• US7247641B2
  申请人：——

  公开号：US7247641B2

  公开（公告）日：2007-07-24
• US8324248B2
  申请人：——

  公开号：US8324248B2

  公开（公告）日：2012-12-04